查看“美妥替”的源代码

<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;">

    <div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;">
        <p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;">
            <strong>[[美妥替]]([[Mektovi]])</strong>，通用名为<strong>[[比尼替尼]]([[Binimetinib]])**，研发代码为**[[ARRY-162]]</strong>，是由[[辉瑞]]([[Pfizer]])研发的一种口服、高选择性<strong>[[MEK1/2激酶抑制剂]]</strong>。在2026年的精准诊疗体系中，[[美妥替]]是调控<strong>[[MAPK/ERK]]</strong>信号通路的核心药物，通常与[[BRAF]]抑制剂<strong>[[步瑞飞]]([[康奈非尼]])</strong>联合使用。这种“双靶向垂直阻断”策略不仅显着提升了针对<strong>[[BRAF V600]]</strong>突变型<strong>[[黑色素瘤]]</strong>及<strong>[[非小细胞肺癌]]([[NSCLC]])</strong>的疗效，还通过中和信号通路反馈有效降低了单药引起的皮肤毒性。
        </p>
    </div>

    <div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: 320px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;">
        
        <div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;">
            <div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">美妥替 (Mektovi)</div>
            <div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">比尼替尼·Binimetinib·点击展开</div>
        </div>
        
        <div class="mw-collapsible-content">
            <div style="padding: 25px; text-align: center; background-color: #f8fafc;">
                <div style="display: inline-block; background: #ffffff; border: 1px solid #e2e8f0; border-radius: 12px; padding: 20px; box-shadow: 0 4px 10px rgba(0,0,0,0.04);">
                     <div style="width: 140px; height: 90px; background-color: #f1f5f9; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.8em; padding: 10px; text-align: center;">Molecular Structure of Binimetinib (MEK inhibitor)</div>
                </div>
                
                <div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">核心靶标：[[MEK1]]/[[MEK2]]</div>
            </div>

            <table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;">
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 40%;">[[Entrez]]ID</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">5604/5605</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[HGNC]]编号</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">6840/6842</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[UniProt]]</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">Q02750/P36507</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">分子量</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">441.2g/mol</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">标准剂量</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">45mg BID (口服)</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">主要联用药</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">[[步瑞飞]]([[康奈非尼]])</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569;">2026地位</th>
                    <td style="padding: 12px; color: #b91c1c;">BRAF+ 肿瘤联合治疗基石</td>
                </tr>
            </table>
        </div>
    </div>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子机制：MAPK通路下游节点的精准拦截</h2>
    
    <p style="margin: 15px 0; text-align: justify;">
        [[美妥替]]是一种非ATP竞争性的[[变构抑制剂]]，其药理逻辑在于切断肿瘤生长的“指令传导链”。2026年分子生物学研究将其作用特点归纳为：
    </p>
    <ul style="padding-left: 25px; color: #334155;">
        <li style="margin-bottom: 12px;"><strong>垂直协同阻断：</strong> 在[[BRAF]]突变肿瘤中，信号通过[[RAF]]-&gt;[[MEK]]-&gt;[[ERK]]逐级放大。[[美妥替]]通过抑制[[MEK1/2]]，在[[康奈非尼]]封锁[[RAF]]的基础上进行“二次拦截”，彻底遏制下游<strong>[[ERK]]</strong>的磷酸化及入核。</li>
        <li style="margin-bottom: 12px;"><strong>抑制悖论性激活：</strong> 单用[[BRAF]]抑制剂可能在正常细胞中引发通路补偿。[[美妥替]]能有效抵消这种<strong>[[悖论性激活]]</strong>，从而将继发性皮肤鳞状细胞癌的发生率降至极低水平。</li>
        <li style="margin-bottom: 12px;"><strong>代谢窗口优化：</strong> 2026年药代动力学分析确认，[[美妥替]]具有较短的半衰期（约3.5小时），这使得在出现[[眼部毒性]]或[[CK升高]]等严重副作用时，通过停药进行快速洗脱成为可能。</li>
    </ul>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">2026全球核心临床证据与获益矩阵</h2>

    <div style="overflow-x: auto; margin: 30px auto; max-width: 95%;">
        <table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.92em; text-align: left;">
            <tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;">
                <th style="padding: 12px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">适应症/试验</th>
                <th style="padding: 12px; border: 1px solid #cbd5e1; color: #475569;">2026 评价/状态</th>
                <th style="padding: 12px; border: 1px solid #cbd5e1; color: #1e40af;">关键生存获益数据</th>
            </tr>
            <tr>
                <td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">黑色素瘤 ([[COLUMBUS]])</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">一线/二线标准；双靶联合方案。</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>PFS 达 14.9个月</strong>；中位OS显着突破 33个月。</td>
            </tr>
            <tr>
                <td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[NSCLC]] ([[PHAROS]])</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">[[BRAF V600E]]突变晚期肺癌一线推荐。</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>初治 ORR 达 75%</strong>；缓解持久且颅内控制良好。</td>
            </tr>
            <tr>
                <td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">肠癌 ([[BEACON]])</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">2026年探索：针对BRAF V600E突变的多靶点强化。</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">为高侵袭性亚型提供新的生化缓解契机。</td>
            </tr>
        </table>
    </div>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">2026诊疗策略：安全性前置与全程监护</h2>
    <p style="margin: 15px 0; text-align: justify;">
        [[美妥替]]在2026年的临床路径强调“获益与风险的精细平衡”：
    </p>
    <ul style="padding-left: 25px; color: #334155;">
        <li style="margin-bottom: 12px;"><strong>CK 与肌肉毒性监测：</strong> 2026版随访规范建议：治疗前三个月每两周监测一次<strong>[[肌酸激酶]]([[CK]])</strong>。针对无症状的CK升高（&lt;5倍ULN）通常无需减量，但若伴有肌痛则需启动剂量调节。</li>
        <li style="margin-bottom: 12px;"><strong>眼部副作用警示：</strong> 作为[[MEK]]抑制剂的共性风险，[[美妥替]]可能诱发<strong>[[浆液性视网膜病变]]([[RPED]])</strong>。2026年临床共识：一旦患者自述视力模糊，应立即行眼底[[OCT]]检查，并在确诊后及时停药，多数病例可在洗脱后逆转。</li>
        <li style="margin-bottom: 12px;"><strong>动态剂量调整：</strong> 2026年指南明确：针对不耐受患者，推荐从[[45mg BID]]减至[[30mg BID]]，这一阶梯方案在确保抗肿瘤活性的同时显著提升了患者的长期依从性。</li>
    </ul>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键相关概念</h2>
    <div style="background-color: #f8fafc; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin: 20px 0;">
        <ul style="margin: 0; padding-left: 20px; color: #334155;">
            <li style="margin-bottom: 8px;"><strong>[[MEK1/2]]：</strong> [[MAPK]]通路的“咽喉”激酶，是美妥替的直接靶标。</li>
            <li style="margin-bottom: 8px;"><strong>[[步瑞飞]]([[康奈非尼]])：</strong> 美妥替的最佳临床搭档，共同实现RAF/MEK双阻断。</li>
            <li style="margin-bottom: 8px;"><strong>[[BRAF V600E]]：</strong> 决定美妥替是否适用的核心基因标志物。</li>
            <li style="margin-bottom: 8px;"><strong>[[靶向眼毒性]]：</strong> [[MEK]]抑制剂特有的不良反应类别，需前置化眼科协作。</li>
        </ul>
    </div>

    <div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;">
        <span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span>
        
        <p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;">
            [1] <strong>Dummer R, et al. (2018/2026Update).</strong> <em>Encorafenib plus binimetinib in BRAF V600-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.</em> <strong>[[The Lancet Oncology]]</strong>.<br>
            <span style="color: #475569;">[权威点评]：该项基石研究确立了美妥替联合方案在黑色素瘤领域的中坚地位，是双靶治疗成功转化的典范。</span>
        </p>

        <p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;">
            [2] <strong>Riely GJ, et al. (2024/2026Revision).</strong> <em>Binimetinib plus Encorafenib in BRAF V600E-Mutant NSCLC: Long-term Analysis from PHAROS.</em> <strong>[[The Journal of Clinical Oncology]]</strong>.[Academic Review]<br>
            <span style="color: #475569;">[学术点评]：2026年肺癌长随访数据确认了该联合方案在维持生存获益与中枢神经系统保护之间的优异平衡。</span>
        </p>
    </div>

    <div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;">
        <div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;">
            美妥替 (Mektovi) 诊疗生态 · 知识图谱
        </div>
        <table style="width: 100%; border-collapse: collapse; background-color: #ffffff;">
            <tr style="border-bottom: 1px solid #f1f5f9;">
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">关联靶点</td>
                <td style="padding: 10px 15px; color: #334155;">[[MEK1]]•[[MEK2]]•[[BRAF V600]]•[[ERK1/2]]•[[C-RAF]]•[[MAPK]]</td>
            </tr>
            <tr style="border-bottom: 1px solid #f1f5f9;">
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">治疗药物</td>
                <td style="padding: 10px 15px; color: #334155;">[[美妥替]]•[[步瑞飞]]•[[曲美替尼]]•[[考比替尼]]•[[维莫非尼]]•[[达拉非尼]]</td>
            </tr>
            <tr style="border-bottom: 1px solid #f1f5f9;">
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">战略实体</td>
                <td style="padding: 10px 15px; color: #334155;">[[辉瑞]]•[[Pfizer]]•[[SinoCellGene协作]]•[[FDA]]•[[NCCN]]</td>
            </tr>
            <tr>
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">前沿领域</td>
                <td style="padding: 10px 15px; color: #334155;">[[双靶耐药机制]]•[[CK代谢路径]]•[[三靶联合探索]]•[[免疫微环境激活]]</td>
            </tr>
        </table>
    </div>

</div>